focus -WSS

focus

author：hotspot 2025-09-02 11:40:49 - browse：71769

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Drug firms test therapies to halt Alzheimer’s before symptoms arise

explore

WSS

CVS is on a mission to consolidate health care. Will it work?

Winners, losers from Medicare’s list of drugs subject to price talks

2024 GOP presidential candidates spar over abortion in debate

Medicare explains how it will choose drugs for negotiation

Cardiologists urge adding sexual orientation, gender identity to health records

Medicare drug price lawsuits could be good politics for Biden

knowledge

focus

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Study finds new variant for Parkinson’s in African populations

Drug repurposing or repositioning? The language matters

As pharma fights Medicare drug negotiation, hospitals, docs silent

23andMe had bad news about my health. I wish a person had delivered it

Pumping milk in bathrooms at health conferences is common

Psychedelics group wrestles with new pharma identity

In science, is the line between industry and academia shifting?

As demand for Covid shots wanes, Moderna seeks its next success

How Long Island became the ‘eugenics capital of the world’

entertainment

Medicare bonuses could stop drug shortages under Senate plan

How Long Island became the ‘eugenics capital of the world’

Cardiologists urge adding sexual orientation, gender identity to health records

Why more medical students aren't specializing in primary care

Printout prescription drug information shouldn’t go digital

Dana Farber says 6 studies to be retracted and 31 corrected

focus

explore

hotspot

hotspot